Hafize Aysin Akpinar
A5090047184- Autophagy in Disease and Therapy
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Cannabis and Cannabinoid Research
- bioluminescence and chemiluminescence research
- Lymphoma Diagnosis and Treatment
- Lipid metabolism and biosynthesis
- Protein Degradation and Inhibitors
- Mycotoxins in Agriculture and Food
- Crystallization and Solubility Studies
- Parkinson's Disease Mechanisms and Treatments
- Cancer therapeutics and mechanisms
- X-ray Diffraction in Crystallography
Institute of Cancer Research
2019-2023
Cancer Research UK
2019-2022
Boğaziçi University
2019
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered field. Our knowledge base relevant new technologies also been expanding. Thus, it is important to formulate on a regular basis updated monitoring autophagy different organisms. Despite numerous reviews, there continues be confusion regarding acceptable methods evaluate autophagy, especially multicellular...
Ochratoxin A (OTA) is a carcinogenic mycotoxin, which produced by Aspergillus and Penicillium genera of fungi commonly contaminates food feed. We others have previously shown that OTA causes sustained activation PI3K/AKT MAPK/ERK1-2 signaling pathways in different cell types animal models. Given the close relationship between cellular activity protein stability, we were curious whether increased may be result OTA-stimulated alterations proteolytic activity. show both major systems,...
B-cell lymphoma 6 (BCL6) is a transcriptional repressor and oncogenic driver of diffuse large (DLBCL). Here, we report the optimization our previously reported tricyclic quinolinone series for inhibition BCL6. We sought to improve cellular potency in vivo exposure non-degrading isomer, CCT373567, recently published degrader, CCT373566. The major limitation inhibitors was their high topological polar surface areas (TPSA), leading increased efflux ratios. Reducing molecular weight allowed us...
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 CCT373566, a highly potent probe suitable for sustained depletion vivo. We observed sharp degradation SAR, where subtle structural changes conveyed ability induce BCL6. CCT373566 showed modest vivo efficacy lymphoma xenograft mouse model following oral dosing.